DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial
DalCor Pharmaceuticals today announced the opening of multiple international clinical trial sites in New Zealand and Europe for its Phase 3 dal-GenE clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene.
